SillaJen Inc (215600) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SillaJen Inc (215600) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.74 Billion ≈ $-3.21 Million USD) by net assets (₩117.80 Billion ≈ $79.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is SillaJen Inc worth for the company's overall valuation and market capitalisation.
SillaJen Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how SillaJen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SillaJen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SillaJen Inc ranked by their cash flow conversion efficiency. See SillaJen Inc (215600) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASIX Electronics
TWO:3169
|
0.042x |
|
Banque Cantonale Du Jura SA
SW:BCJ
|
0.186x |
|
Havilah Resources Ltd
AU:HAV
|
-0.017x |
|
Export Inv
TA:EXPO
|
0.037x |
|
Acsion Ltd
JSE:ACS
|
0.034x |
|
Roda Vivatex Tbk
JK:RDTX
|
0.003x |
|
Future Park Leasehold Property Fund
BK:FUTUREPF
|
0.037x |
|
Kwangdong Phar
KO:009290
|
-0.015x |
Annual Cash Flow Conversion Efficiency for SillaJen Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. View latest SillaJen Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩131.82 Billion ≈ $89.33 Million |
₩-17.83 Billion ≈ $-12.08 Million |
-0.135x | +54.44% |
| 2023-12-31 | ₩57.31 Billion ≈ $38.84 Million |
₩-17.02 Billion ≈ $-11.53 Million |
-0.297x | -5.86% |
| 2022-12-31 | ₩78.94 Billion ≈ $53.50 Million |
₩-22.14 Billion ≈ $-15.00 Million |
-0.280x | +50.07% |
| 2021-12-31 | ₩108.05 Billion ≈ $73.22 Million |
₩-60.69 Billion ≈ $-41.13 Million |
-0.562x | +43.98% |
| 2020-12-31 | ₩22.88 Billion ≈ $15.51 Million |
₩-22.94 Billion ≈ $-15.55 Million |
-1.003x | -241.83% |
| 2018-12-31 | ₩165.09 Billion ≈ $111.88 Million |
₩-48.43 Billion ≈ $-32.82 Million |
-0.293x | -275.11% |
| 2017-12-31 | ₩201.95 Billion ≈ $136.86 Million |
₩33.83 Billion ≈ $22.93 Million |
0.168x | +117.60% |
| 2016-12-31 | ₩207.97 Billion ≈ $140.94 Million |
₩-197.98 Billion ≈ $-134.17 Million |
-0.952x | -269.66% |
| 2015-12-31 | ₩86.94 Billion ≈ $58.91 Million |
₩-22.39 Billion ≈ $-15.17 Million |
-0.258x | -- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more